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Abstract: The application of high-throughput sequencing technologies to non-model organisms
has brought new opportunities for the identification of bioactive peptides from genomes and
transcriptomes. From this point of view, marine invertebrates represent a potentially rich, yet
largely unexplored resource for de novo discovery due to their adaptation to diverse challenging
habitats. Bioinformatics analyses of available genomic and transcriptomic data allowed us to identify
myticalins, a novel family of antimicrobial peptides (AMPs) from the mussel Mytilus galloprovincialis,
and a similar family of AMPs from Modiolus spp., named modiocalins. Their coding sequence
encompasses two conserved N-terminal (signal peptide) and C-terminal (propeptide) regions
and a hypervariable central cationic region corresponding to the mature peptide. Myticalins are
taxonomically restricted to Mytiloida and they can be classified into four subfamilies. These AMPs
are subject to considerable interindividual sequence variability and possibly to presence/absence
variation. Functional assays performed on selected members of this family indicate a remarkable
tissue-specific expression (in gills) and broad spectrum of activity against both Gram-positive and
Gram-negative bacteria. Overall, we present the first linear AMPs ever described in marine mussels
and confirm the great potential of bioinformatics tools for the de novo discovery of bioactive peptides
in non-model organisms.
Keywords: antimicrobial peptide; innate immunity; Mytilus galloprovincialis; proline-rich;
hypervariability
1. Introduction
Antimicrobial peptides (AMPs) are fundamental effector molecules of the humoral innate immune
system that are widespread in animals and contribute to the first line of defense against pathogens.
Expansion and diversification of both innate immune receptors and effectors is a common finding
in animals, especially in invertebrate organisms that lack an adaptive immune system [1,2]. AMP
research in mollusks is indissolubly linked to marine mussels (Mytilus spp.) since the mid-1990s, when
active hemolymph fractions were used to purify several short cysteine-rich peptides, belonging to the
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defensin, mytilin, myticin and mytimycin families [3,4]. These AMPs are all expressed at high levels
in hemocytes, circulating cells that are considered to be major players in molluscan immunity, and
are all characterized by multiple disulfide bridges which ensure a precisely folded, stable structure
for the mature peptides that are compact, cationic and amphipathic in nature. Although more recent
reports have provided evidence for the presence of AMPs in other mussel tissues [5–7], a finding in
line with the emerging role of mucosal immunity in bivalves [8,9], all currently known mussel AMPs
can be placed within the cysteine-rich category based on the conventional structural classification of
AMPs [10].
It is, in fact, rather puzzling that no AMPs belonging to the two other major and widespread
structural categories, namely linear/α-helical AMPs and AMPs enriched in specific amino acids has
ever been reported in Mytilus spp. and other mytiloids. Reports from other molluscan species are
however still quite scant, possibly due to poor sequence homology with known AMPs of other phyla
and the consequently difficult identification by sequence similarity-based methods [11].
As far as bivalve mollusks are concerned, the most remarkable case is certainly that of
molluscidins, short and likely unstructured AMPs characterized by multiple dibasic residue repeats,
identified in the gills of oysters (Bivalvia) and abalones (Gastropoda) [12,13]. Although the two
reported molluscidins display similar length and amino acid composition, the lack of structural data
for the abalone gene and the apparent absence of similar sequences in the available genomes of
other mollusks [14,15] do not permit the assessment with any certainty as to whether these two gene
products are orthologous or the product of convergent evolution. Moreover the organization of their
protein precursors is quite unusual since it is devoid of signal peptide and an anionic pro-region.
In any case, both molluscidins displayed a similarly broad spectrum of activity against bacteria, but
were inactive against Candida spp. Furthermore, the inducibility of the oyster peptide upon injection
of Vibrio sp., supports the involvement of linear cationic peptides in the molluscan immune defense.
Another example is provided by CgPrps (proline- and arginine-rich peptides) identified in the
hemocytes of the Pacific oyster Crassostrea gigas. Although these peptides did not display any significant
antimicrobial activity by themselves, they were able to synergistically enhance the activity of defensins
co-occurring in stimulated hemocytes [16]. The only other account of AMPs devoid of cysteine residues
in mollusks is related to Rapana venosa, a marine snail where multiple cationic Pro-rich AMPs with no
similarity with any publicly available sequence have been isolated from the hemolymph [17].
However, linear cationic AMPs are not rare in other invertebrate taxa, arthropods in particular.
Crab arasins, [18] hyastatins [19] and shrimp penaeidins [20,21] are highly diverse AMPs, all rich
in Pro and Arg residues and only seldom associated with an additional domain bearing disulfide
bridges. Metalnikowins from the hemipteran Palomena frasina [22], drosocins and metchnikowins from
Drosophila [23,24], formaecins from the ant Myrmecia gulosa [25], oncocins and pyrrhocoricins from the
sap-sucking-bug Pyrrhocoris apterus [26,27], lebocins from the silkworm Bombyx mori [28], astacidins
from the freshwater crayfish Procambarus clarkii [29] and the large family of Pro-rich apidaecins
from the honeybee Apis mellifera [30], are just some other examples of linear AMPs from nonmarine
invertebrate organisms.
Taking into account the large disparity in the available literature related to linear AMPs in
ecdysozoan and non-ecdysozoan protostomes, we developed an analytical pipeline to efficiently
identify AMP-encoding transcripts in M. galloprovincialis, an organism with an abundant repertoire of
defense peptides. This transcriptome-based approach relied on the detection of sequences encoding
short secreted peptides with chemical-physical properties similar to other known cationic AMPs. The
applied analysis did not rely on significant sequence similarity with other AMPs or the presence of
known protein domains, thus overcoming inherent difficulties of routine bioinformatics methods in
the detection of novel AMPs.
Overall, we could identify and characterize a large new family of potential AMPs, proposed
here as myticalins, mainly expressed in mussel gills as prepropeptides. Their considerable diversity,
both at the genomic DNA and mRNA level, suggests that these sequences are subject to diversifying
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evolution. The antimicrobial properties of seven chemically synthesized myticalins, were confirmed
in vitro against a broad range of Gram-positive and Gram-negative bacteria.
2. Results and Discussion
2.1. Myticalins Pertain to a Multigenic Family
Following an in silico AMP discovery approach, we identified a transcript encoding a precursor
protein targeted to the canonical secretory pathway. The signal peptide for secretion was followed
by a highly positively charged region rich in proline, arginine and tyrosine residues arranged as PRY
repeats, and by a negatively charged C-terminal region rich in aspartic and glutamic acid residues.
These two regions with opposite charge were separated by a dibasic lysine/arginine proprotein
convertase cleavage site. The chemical-physical properties and amino acid composition of the central
region denoted a high antimicrobial potential, suggesting that it might correspond to a mature peptide
released upon secretion of its precursor polypeptide into the extracellular space and further propeptide
removal. Due to the absence of predictable secondary structure and its highly cationic character, the
putative mature peptide was provisionally named myticalin, acronym for Mytilus cationic linear AMP.
Subsequent BLAST searches in the available mussel transcriptomes revealed many additional
myticalin-like sequences, sharing high homology with each other mostly in the N-terminal
signal peptide or in the C-terminal anionic extension, but only seldom in the central mature
peptide region. The multiple alignment of the 28 full-length sequences identified in Mytilus
spp. revealed some peculiar features shared by all myticalins (Figure 1). In the first place, the
entire signal peptide region was well conserved in all sequences (50% majority-rule consensus
sequence = MKGXXLLLLTIXXALCMIXECEG), as often reported for other AMPs [31–33] and
toxins [34,35]. The Lys-Arg dibasic site was conserved in nearly all sequences, whereas the anionic
C-terminal extension of variable length (35–75 amino acids) displayed moderate conservation.
Notably, the central, mature peptide region was found to be extremely variable, both in terms of
length (ranging from 23 to 42 residues) and amino acid composition. Notwithstanding their limited
sequence homology, all the putative mature peptide regions shared a high isoelectric point (>11) and
>10% content of arginine residues. Frequently, the cleavage of the anionic extension was predicted
to result in a Gly/Arg dipeptide at the C-terminus of the central region, which is expected to lead
to the C-terminal amidation of the amino acid residue N-terminal to Gly, by the combined action of
carboxypeptidase E (CPE) and peptidylglycine α-amidating monooxygenase (PAM). This is a common
feature of AMPs that serves to increase cationicity and reduce degradation, and may have functional
consequences [36].
Further analysis of the amino acid content of myticalins and reciprocal similarity observed in the
multiple sequence alignment reported in Figure 1 allowed the classification of these AMPs into four
subfamilies: (i) A, rich in Arg, Pro and Tyr residues (>10% each); (ii) B, containing a single member, rich
in Pro, Arg and Thr residues; (iii) C, rich in Arg, but nearly devoid of Pro residues; (iv) D, rich in Pro Arg
and Trp (or Thr) residues. Myticalins were named using a two-symbol code, with a letter indicating the
group, and a number distinguishing the group member. Focusing on the physicochemical properties
of the inferred mature peptide, the proposed classification does not consider the species of origin
(owing to genetic introgression a specific myticalin may occur in more than one species of M. edulis sp.
complex), minor polymorphisms occurring in the signal peptide/propeptide regions or synonymous
nucleotide substitutions. The full length myticalin sequences identified in this study have been
deposited in GenBank with the accession IDs MF432160–MF432186.
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Figure 1. Multiple sequence alignment of all myticalin precursor sequences identified in Mytilus spp. 
Signal peptide, mature peptide region, dibasic propeptide cleavage site and anionic C-terminal 
extension regions are highlighted. Amino acids are colored according to their chemical-physical 
properties. All the reported sequences pertain to the Mytilus edulis species complex (M. 
galloprovincialis, M. edulis, M. trossolus and M. chilensis), with the exception of myticalin A1, A2, A6, 
A7, C4 and C7, which were identified in M. californianus. 
Such categorization nearly perfectly mirrored the phylogenetic relationship of sequences, based 
on their alignable portions (i.e., not taking into account mature peptide divergent regions), and the 
three major groups (A, C and D) were supported by extremely significant posterior probability values 
(Figure 2). Myticalin B1, clustered apart from the three aforementioned myticalin subfamilies, in 
agreement with its peculiar amino acid composition. Despite their significant divergence, myticalins 
C and D were more closely related to each other than with myticalins A or B. The divergence between 
the M. californianus myticalin A1/A2 and the other group A myticalins can be linked to the unusually 
short C-terminal extension of the former (Figure 1). 
Figure 1. Multiple sequence alignment of all myticalin precursor sequences identified in Mytilus
spp. Signal peptide, mature peptide region, dibasic propeptide cleavage site and anionic C-terminal
extension regions are highlighted. Amino acids are colored according to their chemical-physical
properties. All the reported sequences pertain to the Mytilus edulis species complex (M. galloprovincialis,
M. edulis, M. trossolus and M. chilensis), with the exception of myticalin A1, A2, A6, A7, C4 and C7,
which were identified in M. californianus.
Such categorization nearly perfectly mirrored the phylogenetic relationship of sequences, based
on their alignable portions (i.e., not taking into account mature peptide divergent regions), and
the three major groups (A, C and D) were supported by extremely significant posterior probability
values (Figure 2). Myticalin B1, clustered apart from the three aforementioned myticalin subfamilies,
in agreement with its peculiar amino acid composition. Despite their significant divergence, myticalins
C and D were more closely related to each other than with myticalins A or B. The divergence between
the M. californianus myticalin A1/A2 and the other group A myticalins can be linked to the unusually
short C-terminal extension of the former (Figure 1).
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Figure 2. Unrooted Bayesian phylogenetic tree summarizing the relationships among myticalins. The 
tree topology is based on the multiple sequence alignment of the nucleotide sequences encoding the 
precursor proteins of myticalins, with the hypervariable mature peptide region removed. Codon 
triplets were preserved and the tree topology was calculated based on a codon w variation model of 
molecular evolution. Only posterior probability support values for the major nodes are displayed for 
clarity’s sake. All the sequences displayed in the tree pertain to the Mytilus edulis species complex (M. 
galloprovincialis, M. edulis, M. trossolus and M. chilensis), with the exception of myticalin A1, A2, A6, 
A7, C4 and C7, which were detected in M. californianus. 
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The exon/intron architecture of myticalin genes was investigated in the publicly available draft 
genome of M. galloprovincialis [37]. However, the high fragmentation of the genome impaired a 
detailed study of the genomic context, association with neighboring genes and myticalin promoter 
regions. Nevertheless, we could retrieve the full-length sequence of two genes, encoding myticalin 
A5 and C10, each one composed by three exons and two introns. Partial genomic data for other 
myticalins fully confirmed the consistency of exon/intron boundaries for all the members of this 
family. In detail, the first short exon exclusively contains the 5’UTR region (Figure 3). The first 
relatively short intron (303 bp or 340 bp) interrupts the 5’UTR region right before the ATG start codon, 
which is therefore located at the 5’ end of exon 2. Exon 2 encompasses the entire signal peptide, the 
complete mature peptide region, the dibasic propeptide cleavage site and the first few residues of the 
anionic extension. The second intron is in phase 1 and displays a marked length difference between 
the myticalin C10 and A5 genes (289 bp and 1,287 bp, respectively). The third and final exon encodes 
the remaining part of the precursor C-terminal extension, and includes the 3’UTR region up to the 
polyadenylation signal (Figure 3). 
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C10, each one composed by thr e exons and two introns. Partial genomic data for other myticalins
fully onfirmed the consistency of exon/i tron boundaries for all the members of this fa ily. In detail,
the first short exon exclu ively contai s the 5′UTR region (Figure 3). The first relatively short intron
(303 bp or 340 bp) interrupts the 5′UTR region right before th ATG start codon, which is therefore
located at the 5′ end of xon 2. Exon 2 encompasses the entire signal peptide, the complete matur
peptid region, the dibasic propeptide cleavage sit an th first few resi ues of the anionic extension.
The se ond i tr is in phase 1 and di plays marke length differenc between the myticalin C10
and A5 genes (289 bp and 1287 bp, respectively). The third and final exon encodes the remaining part
of the precursor C-terminal extensi n, and includ s the 3′UTR region up to the polyadenylation signal
(Figure 3).
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Figure 3. (a) Gene structure of myticalin A5 and myticalin C10, deduced by the alignment of de novo 
assembled transcripts with the draft reference genome of Mytilus galloprovincialis [37]. The mature 
peptides generated by the post-translational processing of the prepropeptides encoded by the two 
genes are also indicated, highlighting proline (yellow), arginine (red) and tyrosine (blue) residues and 
indicating positive net charges at pH = 7. (b) Typical organization of myticalin mRNAs. 
The simultaneous availability of a completely assembled genome and of the corresponding raw 
sequencing data gave us the opportunity to investigate in detail the full complement of myticalin 
genes present in the genome of a single mussel specimen. Surprisingly, only four out of the 22 
different precursor variants present in M. galloprovincialis transcriptomes (see Figure 1) were detected, 
indicating a lower than expected level of genomic complexity. While the absence of some myticalin 
genes could be potentially explained by the genome assembly fragmentation, these results were 
confirmed by multiple bioinformatics approaches, i.e., the independent reassembly of raw 
sequencing data using the CLC Genomics Workbench 10 (Qiagen, Hilden, Germany) and the 
mapping of the reads against full-length myticalin ORFs. The latter approach ruled out the possibility 
that missing myticalin genes were contained in unassembled genomic regions, as no read could be 
unambiguously mapped on such sequences, whereas the expected genome sequencing coverage was 
estimated to be ~30× [37]. 
Three of the genes identified pertained to group A (A3, A4 and A5) and a single gene pertained 
to group C (C10) (Table 1). As mentioned above, the genes A5 and C10 were complete, as they 
contained the three exons within the same contig, whereas the other myticalin genes were fragmented 
between two or three contigs. Neither the myticalin B1 gene nor any functional myticalin pertaining 
to group D could be found in the draft mussel genome. However, we could identify three myticalin 
pseudogenes with no evidence of expression. The first one showed 97% sequence identity to 
myticalin C3 and contained a nonsense mutation (confirmed by 100% mapped reads) within exon 2, 
expected to produce a truncated precursor. The second one showed 97% sequence identity to 
myticalin D7 and presented a large deletion within exon 2, expected to cause the loss of the signal 
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The simultaneous availability of a completely assembled genome and of the corresponding raw
sequencing data gave us the opportunity to investigate in detail the full complement of myticalin
genes present in the genome of a single mussel specimen. Surprisingly, only four out of the 22 different
precursor variants present in M. galloprovincialis transcriptomes (see Figure 1) were detected, indicating
a lower than expected level of genomic complexity. While the absence of some myticalin genes could
be potentially explained by the genome assembly fragmentation, these results were confirmed by
multiple bioinformatics approaches, i.e., the independent reassembly of raw sequencing data using
the CLC Genomics Workbench 10 (Qiagen, Hilden, Germany) and the mapping of the reads against
full-length myticalin ORFs. The latter approach ruled out the possibility that missing myticalin genes
were contained in unassembled genomic regions, as no read could be unambiguously mapped on such
sequences, whereas the expected genome sequencing coverage was estimated to be ~30× [37].
Three of the genes identified pertained to group A (A3, A4 and A5) and a single gene pertained
to group C (C10) (Table 1). As mentioned above, the genes A5 and C10 were complete, as they
contained the three exons within the same contig, whereas the other myticalin genes were fragmented
between two or three contigs. Neither the myticalin B1 gene nor any functional myticalin pertaining
to group D could be found in the draft mussel genome. However, we could identify three myticalin
pseudogenes with no evidence of expression. The first one showed 97% sequence identity to myticalin
C3 and contained a nonsense mutation (confirmed by 100% mapped reads) within exon 2, expected
to produce a truncated precursor. The second one showed 97% sequence identity to myticalin D7
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and presented a large deletion within exon 2, expected to cause the loss of the signal peptide region.
The correct assembly of the corresponding contig was confirmed by two assembly methods and by a
consistent coverage of paired-end reads coverage. The third pseudogene, also pertaining to group D,
did not share high similarity to any of the other myticalins and presented an ORF interrupted by two
nonsense mutations within exon 2, fully confirmed by 100% mapped reads. The finding of multiple
myticalin pseudogenes recalls a common feature of hypervariable gene families quickly evolving by
gene duplication, such as those encoding toxins and defense peptides [34,38].
Table 1. Myticalin genes and pseudogenes detected in the Mytilus galloprovincialis draft genome.
Gene Genomic Scaffold Predicted Mature Peptide Sequence
Myticalin A3 8059-668075 YGWPRMPRIPRKPRYPRYPRYPRWPRHPTIYA-NH2
Myticalin A4 11814-355 YSWPRMPRIPRLPRYPRYPRYPRYPRWPRHPTIYA-NH2
Myticalin A5 371709-C71912861-576740 YSWPRMPRIPRLPRYPRYPRYPRWPRWPRQPTIYA-NH2
Myticalin C10 281970-C72301332 GRRRRYRYWRRGYRSWRRGVTIQERSKSSTLNTED
Myticalin C-PG 410031 RRRRRYRYWRRGLTI*GRSKSLPLNTGD 1
Myticalin D-PG1 8059 WGRRWRV*IPSPPRIRPWPP*TWPRPKWPRSATINID 1
Myticalin D-PG2 266177 WGRRLRIRIPSPPRPRPWPRPYPGPWPRSATINTDQ 2
PG: pseudogene. 1 virtual peptide, containing in frame STOP codons; 2 virtual peptide, with exon 2 partially deleted.
* indicates nonsense mutations.
Overall, we report the presence of just four potentially functional myticalin genes pertaining to
groups A and C in the draft mussel genome. Group D was represented by two pseudogenes and
group B was not represented at all. These results suggest that considerable interindividual variability
might occur in the inventory of myticalin genes across mussels, to the point that each individual could
present a unique gene set, similarly to what has previously been reported for other AMPs in Mytilus
spp. [5,39]. However, it remains to be established whether this variation is the result of extreme allelic
variability linked to high heterozygosity [37], widespread genetic introgression within the M. edulis
species complex [40] or whether it is linked to genome-wide phenomena of presence/absence variation,
which have been previously described in oyster big defensins [41].
To test this hypothesis, we designed gene-specific primer pairs and preliminary tested the
occurrence of different myticalins in 20 mussels, collected in the Gulf of Trieste (Italy) and belonging to
the same natural population (Table S1). The successful amplification of myticalin C2, C5 and D1/D2
confirmed the presence of the corresponding genes in all the 20 tested genomes. On the other hand,
in other cases we obtained an amplification product only in a few (C7) or in no mussel at all (C8),
strongly hinting that these genes are not ubiquitously present. Further support of the presence/absence
hypothesis was obtained with primers designed to co-amplify multiple myticalin genes, as a single or
multiple amplification products (in particular for myticalin group A sequences), or no amplification at
all (in some specimens, for myticalin D3/D4/D5) were evident.
Only the release of an improved assembly and annotation of the mussel genome and the
resequencing of multiple individuals will provide definitive evidence for the possible involvement
of presence/absence gene variability as a basis for the wide levels of interindividual variability
of myticalins.
2.3. Myticalins Are Taxonomically Restricted to Mytiloida
Comparative genomics and transcriptomics analyses were employed to narrow down the
distribution range of myticalins to a limited number of species pertaining to the order Mytiloida
(Mollusca, Bivalvia). While no genome or transcriptome data is currently available for several minor
lineages within the Bivalvia class, current data is certainly sufficient to exclude the presence of
myticalins in non-mytiloid bivalves. Indeed, no myticalin-like sequence could be detected in the fully
sequenced genomes of oysters and scallops [14,42,43], neither in the several dozen transcriptomes
screened from Pteriomorphia, Heterodonta, Palaeoheterodonta, Archiheterodonta and Protobranchia
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(Table S2). Furthermore, neither BLAST nor HMM-based approaches led to the identification of
significant similarities in non-bivalve mollusks and other metazoans.
However, the analysis of available sequence data, indicated a patchy taxonomical distribution of
myticalins even within the order Mytiloida, evidencing an apparent restriction to Mytilus and Modiolus
spp. (Figure 4). Due to the marked divergence between Mytilus and Modiolus sequences, the latter
were named modiocalins, as detailed in the next section. In detail, we detected myticalin sequences in
all the interfertile species pertaining to the Mytilus edulis species complex (M. galloprovincialis, M. edulis,
M. trossolus and M. chilensis) and, often, an identical sequence could be identified in multiple species,
in agreement with the widespread genetic introgression already reported in this complex of species [40].
Myticalins of group A (A1, A2 and A6) or C (C4 and C7) were detected in Mytilus californianus, but
no evidence of expression of myticalins B and D could be found in this species. Despite the relevant
amount of RNA-seq data available for Mytilus coruscus, which include RNAs obtained from whole
body, no full-length myticalin sequence was identified in the transcriptome of the Korean mussel.
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33412). These sequences were named modiocalins (Modiolus cationic linear AMPs). Their 
i r . Taxonomic distribution of myticalins (light red) and modiocalins (light blue) within the order
Mytiloida, as inferred by their pres nce/absence in the available tr nscriptomi and genomic sequence
datasets. The Pacific oyster C. gigas was used as an outgroup to root the tree. The topology of the tree
was retri ved from NCBI Taxonomy and the positio of M. virgata was adjusted within Brachi ontinae
based on recent molecula data [44].
The absence of myticalin-like genes in the genome of Bathymodiolus platifrons and in the
transcriptomes of many other mussel species pertaining to Bathymodiolinae (Bathymodiolus az ricus,
Bathymodiolus manusensis), Brachidontinae (Mytilisepta virgata, Perumytilus purpuratus, Geukensia demissa)
Lit phagi ae (L. lithophaga) strongly suggest that myticalin-related sequences are only present i
ome, but not all, mytiloids (Figure 4). The absence of myticalins in Perna viridis and Limnoper a fortunei,
two member of the Mytilinae family together with Mytilus spp., further suggests th t the evolutionary
history of the myticalin gene family is complex and several independent gene loss events might explain
such a taxonomic distribution. In any case, the lack of myticalin sequences within a transcriptome does
not necessarily indicate, by itself, the absence of these genes, but rather just the lack of their expression.
Only the future release of other mytiloid genomes and the analysis of novel sequence resources for
other species will improve the preliminary overview depicted in Figure 4.
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2.4. Modiocalins: Myticalin Homologs in Modiolus spp.
The analysis of the recently released genome of Modiolus philippinarum [45] led to the identification
of three potentially functionally complete myticalin-like genes (Mph_scaf_68178-0.0 and two
unannotated genes located on scaffolds 10967 and 42638), a partial gene (unannotated, on scaffold
21923) and two pseudogenes containing in-frame STOP codons (both located on scaffold 33412).
These sequences were named modiocalins (Modiolus cationic linear AMPs). Their evolutionary
relationship with myticalins derive from several observations: (i) limited but still significant primary
sequence similarity; (ii) identical gene architecture, including the presence of a phase 1 intron in the
same position; (iii) identical protein precursor organization, containing a signal peptide, a central
mature peptide region, a dibasic cleavage site and a C-terminal extension; (iv) high fraction of Pro
and Arg residues in the mature peptide region; (v) prediction of high antimicrobial potential based on
several in silico tools. In addition, modiocalins typically display a shorter and more variable C-terminal
extension, which is nonetheless rich in anionic residues (Figure 5).
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Figure 5. (a) Schematic organization of the M. philippinarum modiocalin-1 gene; (b) Organization
of the M. philippinarum modiocalin-1 mRNA; (c) Multiple sequence alignment of M. philippinarum
(Modphi), M. modiolus (Modmod) and M. kurilensis (Modkur) modiocalins (only full-length sequences
with evidence of expression have been included).
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The sequence of the three full-length genes encoding modiocalin precursor proteins could be
confirmed by the analysis of the de novo assembled transcriptome of M. philippinarum, which enabled
their intron/exon boundaries to be defined in detail and the expression of the corresponding transcripts
to be confirmed (tissue specificity could not be assessed since the RNA-seq data was obtained from a
mix of tissues).
We detected modiocalins also in the gill transcriptome of the closely related species
Modiolus kurilensis: a single functional sequence could be found in this case, while a second transcript
contained an ORF interrupted by a premature STOP codon. Searches conducted in the Modiolus modiolus
transcriptome (obtained from a mixture of gills, mantle and posterior adductor muscle) enabled the
identification of a sequence identical at the amino acid level to that of M. kurilensis and a second one
similar to M. philippinarum modiocalin-4 (Figure 5).
2.5. In Silico Evaluation of Antimicrobial Potential
Most of the 20 myticalins were identified as AMPs by a number of in silico predictor tools
(Table S3). In detail, the antimicrobial character of myticalin mature peptides was predicted by
CAMP3R [46] using three out of the four available prediction algorithms (80% positives with
Discriminant Analysis, and Support Vector Machines, 75% positives with Random Forests). On the
other hand, the CAMP3R prediction with Artificial Neural Network was negative in nearly 90%
of cases.
With a single exception (myticalin C4), all mussel myticalins were identified as potential AMPS
by iAMP-2L [47] and good results were also obtained with the Support Vector Machine approach of
AntiBP2 [48] (75% positives) and with the sliding window approach of AMPA [49] (80% positives, not
including myticalins of group D). The DBAASP predictor [50] was one of the few methods to only
identify a very few myticalin sequences as potential AMPs. ClassAMP [51] marked all myticalins as
antibacterial peptides with the Random Forests approach, whereas mixed results in terms of specificity
(antibacterial, antiviral or antifungal) were obtained with the Support Vector Machine algorithm.
The majority of the applied prediction algorithms indicated most mussel myticalins as potentially
bioactive peptides, with some differences among subfamilies. On average, group A myticalins were
positively evaluated by 8 out of 10 methods, followed by groups C (7.5), B (6) and D (5.6) (Table S3).
Myticalins A3 and C8 had the highest predicted antimicrobial potential (9 out of 10 methods).
Similarity searches with known AMPs listed in the Antimicrobial Peptides Database [52] revealed
that the mature peptide region of myticalins did not share similarity higher than ~45% with any
known AMP reported so far (Table S3). Class A myticalins displayed the highest homology to other
AMPs (40–45%), in particular with arasin-2 expressed in the hemocytes of the small spider crab
Hyas araneus [18], the apidaecin-based, proline-rich peptide A3-APO [53] and mammalian bactenecins
(e.g., the cathelicidins PR-39 and OaBac5) [54,55]. However, these similarities are restricted to the
mature peptide region, and the organization of the protein precursor of myticalins had no significant
resemblance neither with cathelicidins nor with arasins.
We used a number of accessory algorithms to predict other aspects of the possible bioactive
potential of myticalins. Following the conflicting indications obtained from the ClassAMP SVM
algorithm, which indicated some myticalins as potential antiviral peptides, we tested this hypothesis
with AVPpred [56], which only predicted a weak potential for this kind of activity. Furthermore,
dPABBs predicted a negligible anti-biofilm potential for most myticalin peptides [57]. On the contrary,
potential cell-penetrating activity upon interaction with cell membranes was assigned to all myticalins
by CellPPD [58]. While the latter indication will require experimental validation, the in silico activity
evaluation is confirmed as a convenient approach to preliminary define the possible mode of action of
these mussel AMPs.
Mar. Drugs 2017, 15, 261 11 of 23
2.6. In Vitro Assessment of Antimicrobial Actvity
Seven peptides representative of the four main myticalin groups (Figure 2) were selected for solid
phase synthesis and validation of the antimicrobial activity in terms of bacterial growth inhibition
through minimum inhibiting concentration (MIC) assays. The selected peptides were tested against
different Gram-positive and Gram-negative bacterial strains of environmental or medical relevance,
not only to start exploring their spectrum of activity, but also to evaluate their potential as leading
compounds for the development of new antibiotics (Table 2).
Table 2. Minimal inhibitory concentration (MIC) values for myticalins on selected bacterial strains.
Bacterial Species and Strain
Myticalin (µM)
A5 A8 B1 C6 C9 D2 D5
Escherichia coli ATCC 25922 2 1 8–16 4 4 4 >32
Pseudomonas aeruginosa ATCC 27853 4–8 8 >32 32 8 4 >32
Acinetobcter baumannii ATCC 19606 4 1 8 2 2 2 >32
Vibrio anguillarum ATCC 43305 >32 >32 >32 >32 >32 >32 >32
Staphylococcus aureus ATCC 25923 8–16 16 >32 8 2 16–32 >32
Bacillus subtilis ATCC 6051 4 4 32 32 4 2 >32
MIC values represent the mode of four independent experiments.
Myticalin D5, one of the peptides in silico predicted to have a low antimicrobial potential (Table S3),
was the only one found to be completely inactive (MIC > 32 µM) toward all the tested bacterial strains.
Two other peptides, myticalin B1 and C6, only displayed a moderate antimicrobial activity on a
part of the tested strains. The other four myticalins had a remarkable antimicrobial activity, with
significant MIC values (≤2 µM) against at least one of the tested bacterial strains, confirming the
in silico prediction. Myticalins A5, A8, C9 and D2 displayed a broad spectrum of activity, being
active against Gram-positive and -negative bacteria, although their potential activity in the natural
marine environment remains to be ascertained. The spectrum of antibacterial activity of the Pro-rich
myticalins A5, A8 and D2 interestingly matches that of well characterized linear Pro-rich peptides
(PR-AMPs) previously identified in insects, crustacean and mammals [59], which are mainly active
against Gram-negative species, especially Escherichia coli, Acinetobacter baumannii and, to a lesser extent,
Pseudomonas aeruginosa [60,61], but also displayed a significant activity against the Gram-positive
bacteria Bacillus subtilis. This selectivity derives from the fact that PR-AMPs act internally, and require
a specific cytoplasmic membrane protein transport system to translocate to the cytoplasm, which is
present in some Gram-negative bacterial species (e.g., E. coli and A. baumannii), but not in others (e.g.,
P. aeruginosa) or Gram-positive ones [60,61]. It is worth taking into account that a peculiar, lytic and not
yet fully characterized mode of action has been suggested for PR-AMPs against P. aeruginosa, instead
of the canonical non-lytic mechanism [62].
Myticalin C9 has a very high Arg content (32%) and is not rich in Pro residues. Nevertheless,
it showed an antimicrobial potency to some extent comparable with Pro-rich group A and D myticalins,
except from a significantly higher activity against Staphylococcus aureus (MIC = 2 µM).
None of the peptides inhibited the growth of Vibrio anguillarum ATCC 43305. The high NaCl
content required in the medium for the growth of V. anguillarum is expected to reduce the binding
of AMPs to bacteria and, therefore, their antimicrobial effect. On the other hand, it is also possible
that V. anguillarum, similarly to other vibrios, has evolved intrinsic resistance mechanism towards the
AMPs produced by their typical hosts [63].
2.7. Molecular Mode of Action of Myticalin A5
PR-AMPs can kill bacteria by inhibiting protein synthesis [64,65] by binding the ribosomal exit
tunnel and impairing the elongation step of translation [66,67]. Based on these observations, we chose
the mature peptide of myticalin A5, the richest one in terms of proline content (28%), to assess
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whether it could similarly inhibit protein synthesis in bacteria. As a first approach, a coupled in vitro
transcription/translation reaction was performed in the presence of increasing peptide concentrations.
The initial results indicated a moderate inhibition of the process (Figure S1). In subsequent assays
aimed at dissecting the effects of the peptide on transcription and translation, the inhibiting effect
exerted by the peptide on the translation reaction was surprisingly low (Figure 6a) and became
significant only at 100 µM concentration. On the other hand, the peptide nearly completely inhibited
the RNA synthesis, mediated by the T7 RNA polymerase used in the coupled transcription/translation
reaction, at 10 µM concentration (Figure 6b).Mar. Drugs 2017, 15, 261 12 of 22 
 
 
Figure 6. (a) In vitro translation and (b) in vitro transcription assay in the presence of myticalin A5. 
The positive controls received water instead of the peptide. The negative controls received water 
instead of the peptide and the DNA template encoding the luciferase. The results report the mean 
plus standard deviation of three independent experiments. *** indicate statistical significance p-value 
< 0.05, Student t test. 
2.8. Tissue Specificity 
The analysis of mussel transcriptome data suggested that, in contrast with most AMPs described 
so far in mussels [5–7], myticalins are preferentially expressed in the gills. Indeed, a number of 
myticalin transcripts could be de novo assembled to their full length using gill-derived RNA-seq. reads 
with relatively high sequencing coverage whereas they were only seldom detected in transcriptomes 
of other tissues. 
Following real time quantitative PCR (RT-PCR) assays, we fully confirmed this observation in 
adult unchallenged mussels: myticalins resulted to be mostly expressed in the gills and only barely 
detectable in hemocytes, digestive gland, adductor muscle and foot, inner and outer mantle (Figure 
7). The expression level of myticalins A3/4/5/8/10, B1, C2, C6 and D1/D2 in gills was significantly 
higher than in the other tissues, whereas C5, C8 and D3/D4/D5 could only be detected at trace levels 
in various tissues. Altogether these results are consistent with the increasing recognition of the 
importance of mucosal immunity in marine bivalves [8,9]. Gills, in particular, represent the tissue 
with the broadest interface of interaction with potentially pathogenic microbes present in the water 
and conveyed into the intervalvar space by water filtration. The fibrillary structures of the gills are 
covered with a layer of mucus and they are often associated with complex bacterial communities 
which sometimes cover a function of the utmost importance in bivalve physiology [68,69]. 
It should be stressed out that myticalins maintained a limited expression level, as they remained 
in all cases less than 2% of the housekeeping gene EF1α (Figure 7). This observation is in stark contrast 
with the high constitutive expression of known AMPs in mussel hemocytes [70] and could be 
explained by different factors. First, the high interindividual sequence variability of myticalins and 
the possibility of genetic presence/absence variation, make it possible that primers designed on 
specific sequences may produce an amplification product only for a few of the mussels represented 
in a pooled sample. This would consequently lower the overall expression levels detectable for a 
specific AMP by RT-PCR in relatively large pools (n = 30). Second, we evaluated the myticalin 
expression levels in unchallenged animals, and we cannot rule out an upregulation in response to 
Fig re . (a) In vitro tra slation and (b) in vitr tr scription assay in the presence of yticalin A5.
e siti e tr ls i t The egative controls r ceived ater
i ste eptide and the DNA template ncoding the luciferase. The results report the mean plus
standard deviation of three ind pendent experiments. *** indicate statistic l ignifica ce p-value < 0.05,
Student t test.
Overall, it is reasonable to conclude that the moderate inhibition observed with the coupled
in vitro transcription/translation assay was mainly due to an inhibition of the T7 RNA polymerase
used in this kit to allow the high expression of the reporter gene. Therefore, myticalin A5 is unlikely
to interact with the ribosomal tunnel, thereby blocking the protein synthesis process. The highly
significant inhibiting activity on this peptide on the viral T7 RNA poly erase suggests that it might
have an antiviral effect, despite the poor antiviral potential predicted by in silico methods (Table S3).
2.8. Tissue Specificity
The analysis f mussel transcriptome data suggested that, in contrast with most AMPs described
so far in mu els [5–7], myticalins are preferentially expressed in the gills. Indeed, a number of
myticalin tra scripts could be de novo as embled to their full length using gill-derived RNA-seq. reads
with elatively high sequ ncing cov rage whereas they were only seldom detected in transcriptomes
of other tissues.
Following real ime quanti ative PCR (RT-PCR) ssays, we fully confirmed this observation in
adult unchallenged muss ls: myticalins resulted to be m stly expressed in he gills and only barely
det ctable in hemocytes, digestive gland, adductor mu cle an foo , inner and outer mantle (Figure 7).
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The expression level of myticalins A3/4/5/8/10, B1, C2, C6 and D1/D2 in gills was significantly
higher than in the other tissues, whereas C5, C8 and D3/D4/D5 could only be detected at trace
levels in various tissues. Altogether these results are consistent with the increasing recognition of the
importance of mucosal immunity in marine bivalves [8,9]. Gills, in particular, represent the tissue
with the broadest interface of interaction with potentially pathogenic microbes present in the water
and conveyed into the intervalvar space by water filtration. The fibrillary structures of the gills are
covered with a layer of mucus and they are often associated with complex bacterial communities
which sometimes cover a function of the utmost importance in bivalve physiology [68,69].
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It should be stressed out that myticalins maintained a limited expression level, as they remained
in all cases less than 2% of the housekeeping gene EF1α (Figure 7). This observation is in stark
contrast with the high constitutive expression of known AMPs in mussel hemocytes [70] and could
be explained by different factors. First, the high interindividual sequence variability of myticalins
and the possibility of genetic presence/absence variation, make it possible that primers designed on
specific sequences may produce an amplification product only for a few of the mussels represented in
a pooled sample. This would consequently lower the overall expression levels detectable for a specific
AMP by RT-PCR in relatively large pools (n = 30). Second, we evaluated the myticalin expression
levels in unchallenged animals, and we cannot rule out an upregulation in response to specific and
still unknown pathogenic challenges. Considering these two factors, monitoring the expression of
myticalins should ideally involve the sampling of gills before and after a pathogenic challenge in single
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individuals. Unfortunately, this approach is technically challenging, as it would undermine the health
of animals, possibly resulting in their death.
3. Materials and Methods
3.1. Identification of Myticalin in the Mytilus Galloprovincialis Transcriptome
The previously described transcriptome of the Mediterranean mussel M. galloprovincialis [71]
was subjected to an analysis with TransDecoder v.3.0.1 (http://transdecoder.github.io) to obtain
virtual protein translations of any Open Reading Frame longer than 50 codons and shorter than
120 codons, a length interval which was selected based on the usual length of the precursor protein
sequence of most AMP families found in mollusks and other invertebrates [72]. Only protein products
potentially targeted to the secretory pathway were selected, based on the presence of a signal peptide
region, identified with SignalP 4.1 [73]. Cationic AMP candidates were further selected based on their
chemical-physical properties and amino acid composition, i.e., based on the presence of >30% arginine
or proline residues over a sliding window of 15 amino acids, and/or isoelectric point >8 in a sliding
window of the same length.
The sequences of the resulting candidate peptides were manually checked based on the assessment
of a uniform read coverage by paired-end sequencing reads along the entire coding sequence, to exclude
the possibility of misassembly. A target sequence, provisionally named myticalin (acronym for Mytilus
cationic linear AMP), was selected due to the presence of an evident signal peptide, a central region
satisfying the chemical-physical criteria mentioned above required for the detection of the mature
peptide region, a Lys-Arg dibasic propeptide cleavage site clearly identifiable by ProP 1.0 [74] and a
negatively charged C-terminal region, rich in aspartic and glutamic acid residues, a feature also shared
by mussel defensins, mytilins and myticins [9].
3.2. Identification of Additional Members of the Myticalin Gene Family
Sequence similarity analyses by TBLASTN [75] revealed that myticalin belonged to a sequence
family comprising many different members, which were detected based on an e-value threshold
<1 × 10−5. Therefore, other publicly available transcriptomes from the same species (Table S2), were
screened, with the aim of identifying all the existing sequence variants expressed in different tissues.
The corresponding gene sequences, whenever available, were detected by TBLASTN against the
mussel draft genome [37]. Exon and introns were detected by the alignment of assembled transcripts
with genomic contigs and exon/intron junctions were refined with Genie [76].
Subsequently, the analysis was extended to other bivalve species, based on the dataset of
transcriptomes described in [77] and the available genomes, i.e., C. gigas [42], Pinctada fucata [14],
Mizuhopecten yessoensis [43], Ruditapes philippinarum [78], L. fortunei [79], M. philippinarum and
B. platifrons [45]. A particular focus was pointed to the transcriptomes available for species pertaining to
the order Mytiloida (Table S2), due to their close phylogenetic relationship with Mytilus spp. Another
strategy also used as an alternative to TBLASTN, enabled to detect distantly related sequences.
This was based on the search of an HMM profile, created staring from the MUSCLE multiple
sequence alignment [80] of all Mytilus spp. myticalin sequences, performed with HMMER v.3.1b2 [81].
Due to the inherent limitation of current genome annotation pipelines for non-model metazoans [82],
this approach was applied to the six-frame translations of all genomic scaffolds.
3.3. In Silico Prediction of the Antimicrobial Properties of Myticalins
The protein precursors resulting from the sequence search described above were analyzed with
SignalP 4.1 [73] to identify signal peptide cleavage sites, and with ProP 1.0 [74] to identify dibasic
proprotein convertase cleavage sites. We completed the prediction of mature peptide sequences by
including the removal of C-terminal Arg or Lys residues by CPE and of C-terminal glycine residues by
PAM, thereby resulting in C-terminally amidated peptides. Both molluscan enzymes are structurally
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and functionally similar to their vertebrate homologs and are involved in the post-translational
modification of secreted peptides in gastropods [83,84].
The resulting predicted mature peptides were characterized by the calculation of isoelectric
point with the ExPASy prediction servers (http://web.expasy.org/compute_pi/) and analyzed with
a series of tools for the in silico prediction of antimicrobial activity. These included CAMPR3 (using
the four available prediction algorithms, Random Forests, Discriminant Analysis, Support Vector
Machines and Neural Artificial Network) [46], the predictor of the DBAASP database [50], AntiBP2 [48],
AMPA [49], iAMP-2L [47] and ClassAMP (using both the Random Forests and Support Vector Machine
algorithms) [51]. Furthermore, primary sequence homology with other known AMPs was investigated
with APD3 [52]. The potential antibiofilm and antiviral activities of myticalins were predicted in
silico with the dPABBs server (http://ab-openlab.csir.res.in/abp/antibiofilm/) [57] and AVPpred
(http://crdd.osdd.net/servers/avppred/) [56], respectively. Finally, the cell-penetration activity of
the mature peptides was predicted with CellPPD (http://crdd.osdd.net/raghava/cellppd/) [58].
The secondary structure was predicted with Porter [85].
3.4. Solid Phase Synthesis of Peptides
Seven myticalin peptides (A5, A8, B1, C6, C9, D2 and D5) were chosen on the basis of their
distinctive sequences and mature peptide regions, predicted as described above. The first sequence
was produced in the laboratories of the University of Trieste by solid phase synthesis using Fmoc
chemistry on an Alstra automated microwave synthesizer (Biotage, Uppsala, Sweden). Upon positive
preliminary functional tests, six additional peptide sequences were purchased from Synpeptide Co.,
Ltd. (Shangai, China). All peptides were purified by HPLC (Amersham Pharmacia Biotech, Milan,
Italy) to a purity level >95%, and subsequently verified by MS analysis.
3.5. Bacterial Strains and Evaluation of the Antimicrobial Activity of Myticalins
The following strains have been used in this study: Escherichia coli ATCC 25922, Staphylococcus
aureus ATCC 25932, Vibrio anguillarum ATCC 43305, Pseudomonas aeruginosa ATCC 27853, Acinetobacter
baumannii ATCC 19606, Bacillus subtilis ATCC 6051. Vibrio anguillarum ATCC 43305 was cultivated
in tryptic soy broth (TSB, Becton Dickinson, Milan, Italy) implemented with 2% NaCl, all the other
strains were grown in Müller-Hinton broth (MH, Becton Dickinson, Milan, Italy).
The minimum inhibiting concentration (MIC) of each myticalin synthetic peptide was calculated
using the broth microdilution method [86]. Briefly, twofold serial dilutions of each peptide were
prepared in appropriate growth medium and aliquoted in the wells of a round-bottom microtiter
plates (Sarstedt, Nümbrecht, Germany). An overnight culture of each bacterial strain was diluted
1:50 in fresh growth medium and grown to an OD600nm ≈ 0.3. Each well was then inoculated with a
standardized inoculum in order to achieve, in a final total volume of 100 µL, a final test concentration
of about 5 × 105 CFU/mL. The plate was then sealed to minimize evaporation and incubated at 37 ◦C
for 24 h. The day after, the MIC was identified as the lowest concentration of the peptide that impaired
any visible bacterial growth.
3.6. In Vitro RNA Synthesis, Purification and Quantification
To in vitro synthesize mRNA, in a final volume of 25 µL, 100 ng of a PCR template encoding
firefly luciferase were mixed with 2.5 c of 10× T7 buffer, 100 mM NaCl, 80 mM MgCl2, 20 mM
spermidine (Sigma Aldrich Chemie, Munich, Germany), 800 mM Tris-HCl (Sigma Aldrich Chemie,
Munich, Germany), pH 8.0, DTT (Sigma Aldrich Chemie, Munich, Germany) to a final concentration of
5 mM, NTPs (ATP, GDP, UTP, CTP) (Sigma Aldrich Chemie, Munich, Germany) to a final concentration
of 20 mM, 0.5 µL of RNAse inhibitor (RNAsin®, Promega, Madison, WI, USA) and 1 µL of recombinant
custom-made T7 RNA polymerase (approx. 20 U). One µL of myticalin 5A solution at different
concentrations was added to reach the concentrations of 1 µM, 10 µM and 100 µM. The positive control,
received nuclease-free water instead of myticalin 5A. The negative controls, received nuclease-free
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water instead of myticalin 5A and DNA template. Samples were incubated for 2 h at 30 ◦C under
agitation (300 rpm). Subsequently, all samples were treated with 0.5 U of TURBODNase (Thermo
Fisher Scientific, Whaltam, MA, USA) to remove the DNA template, then centrifuged for 2 min,
12,000× g at 4 ◦C to remove the precipitated pyrophosphate. The cleared supernatants were mixed
with LiCl (Sigma Aldrich Chemie, Munich, Germany) and EDTA (Sigma Aldrich Chemie, Munich,
Germany) to the final concentration of 2.5 M and 17 mM, respectively, in a final volume of 92 µL.
mRNA was precipitated by incubating samples for 1 h at −80 ◦C and by centrifugation for 30 min at
12,000× g and 4 ◦C. The RNA pellets were washed using 70% ethanol, samples were then centrifuged
for 30 min, at 12,000× g and 4 ◦C, the ethanol was removed, the pellets were air dried for 5–10 min
and resuspended in RNase-free water for RNA quantification using a NanoDrop 2000 (Thermo Fisher
Scientific, Waltham, MA, USA) and for quality check by agarose-gel electrophoresis.
3.7. In Vitro Trasncription and Translation Assays
The in vitro translation was performed using the commercial kit RTSTM 100 E. coli HY
(Biotechrabbit, Hennigsdorf, Germany) following the instruction of the supplier. 0.1 µL of RNase
Inhibitor (RNasin®, 20–40 U/µL, Promega, Madison, WI, USA) and 400 ng of synthetic mRNA coding
for the firefly luciferase were added to the reaction mix in a final volume of 5 µL. The positive control
received nuclease-free water instead of myticalin 5A. The negative controls received nuclease-free
water instead of myticalin 5A and mRNA template. 1 µL of peptide solution was then added to the
reactions get a final concentration of 1 µM, 10 µM or 100 µM. Samples were then incubated for 1 h at
30 ◦C with shaking (750 rpm). Subsequently 2 µL of each reaction were mixed with 8 µL kanamycin
(50 mg/mL) to block any residual translation, and diluted with 40 µL of luciferase assays substrate
(Promega, Madison, WI, USA) into a white flat bottom 96-well microtiter plate (Greiner Bio-One,
Kremsmünster, Austria). The activity of the firefly luciferase was assessed and quantified using a Tecan
Infinite M1000 plate reader. The reported relative luminescence data were calculated as a percentage
of the positive control.
3.8. Evaluation of Gene Expression across Tissues
Primers were designed to assess the expression level of myticalins in the main tissues of adult
unchallenged mussel specimens (hemolymph, digestive gland, posterior abductor muscle, inner
mantle, mantle edge, gills and foot). Total RNA, extracted from 30 individuals of roughly the same
size (5–7 cm) all sampled in the Gulf of Trieste (Italy), was quantified, pooled and reverse transcribed
into cDNA like previously described [5].
Due to the relevant sequence similarity of many myticalin variants, some of the primer pairs
designed (Table 3) allowed the simultaneous amplification of multiple highly similar targets. RT-PCR
reaction were carried out on a C1000 thermal cycler (Bio-Rad, Hercules, CA, USA), using the following
thermal profile: (i) initial denaturation at 95 ◦C for 3 min; (ii) 40 cycles at 95 ◦C for 5 s and 55 ◦C for 30 s.
The lack of non-specific amplicons was assessed with a 65 ◦C/95 ◦C melting curve analysis. The PCR
reaction, performed in a 15 µL volume, contained 7.5 µL SsoAdvanced™ SYBR® Green Supermix
(Bio-rad, Helcules, CA, USA), primers (0.3 µL each) and a 1:20 dilution of cDNA.
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Table 3. Primers used for RT-PCR assays.
Sequence Name Forward Primer (5′→ 3′) Reverse Primer (5′→ 3′)
Myticalin A3/A4/A5/A8/A10 MGAATGCCACGGATACCAAG TYATTCGTARMATCATCATTCA
Myticalin B1 GGAAGAAAACGAGCCACT TCAATCCCGTCTCGCTCA
Myticalin D3/D4/D5 GGCRTTCTTTTGYTGTCAATG GATCGTCGCCATGTTGGY
Myticalin D1/D2 TTTTYTTTGCWCTTTGTATGATGG CGTCGTTCAAWATCGCTCG
Myticalin C2 GGCGACGAGGACTTACCATA GCTCGTCGATATCGTCCATTA
Myticalin C8 AAGCCACAGATTGCCAAAAT TCATCCATAACGTCCCCATT
Myticalin C6 GACGAAGGAGGCGAAGATTT TCGTTCATCCKAAATGTCCKTC
Myticalin C5 TGAAAGGGTTTGTTTTGATGC CAGTTCCTCTCTTTTGCGATG
Gene expression levels, representing the mean plus standard deviation of three technical replicates,
were calculated using the ∆Ct method and normalized across tissues based on the housekeeping gene
elongation factor 1 alpha, as described elsewhere [5,87].
3.9. Myticalin Gene Family Evolution
Due to the remarkable diversity of mature myticalin peptide sequences, only the coding part of
the transcripts corresponding to the well-conserved signal peptide region and the C-terminal anionic
extension (including the dibasic cleavage site and the two neighboring N-terminal residues) were
considered for Bayesian phylogenetic inference. Briefly, nucleotide sequences were aligned with
MUSCLE [80], maintaining codon triplets, and the resulting multiple sequence alignment was used
to perform phylogenetic inference with MrBayes 3.2.6 [88], based on a codon w variation model.
The analysis was run for one million generations, until all the estimated parameters of the model
reached convergence. This was assessed with Tracer v.1.6 [89], making sure that all parameters reached
an Effective Sample Size (ESS) value >200.
4. Conclusions
This study highlights the potential usefulness of in silico pipelines as complementary tools for
AMP discovery in genomic and transcriptomic sequence data from non-model organisms. This strategy,
with opportune modifications, appears to be particularly attractive not just for the discovery of AMPs,
but also for the identification of other bioactive gene-encoded products in marine invertebrates, which
can be considered as an invaluable source of natural compounds with potential biotechnological
applications of great interest [90].
The indications obtained from the in silico prediction of antimicrobial potential of myticalins
were confirmed by the positive outcome of microbiological assays, which revealed a potentially broad
spectrum of activity against Gram-positive and Gram-negative bacteria of biomedical or environmental
interest. However, these preliminary results need to be considered within the biological context where
these AMPs are produced and are expected to exert their action. Taking into account the marked tissue
specificity to the gills and the presence of a clear signal peptide for secretion, it seems reasonable that
myticalins are released within the layer of mucus which covers the entire surface of this tissue, which
represents the major interface of contact with the water column in filter-feeding bivalves and harbor of a
complex microbiota [68,69]. Future studies could be focused on a better understanding of the biological
targets of myticalins, to define whether they can be employed as routine microbiome-controlling agents
or as specific killers of pathogenic bacteria.
Although the antibacterial activity of some myticalins could be attained at relatively low MIC
concentrations (2–4 µM), the mode of action of these peptides remains to be elucidated. Like other
PR-AMPs, myticalins were predicted to have relevant cell-penetrating properties, but preliminary tests
have clearly shown that they are characterized by a divergent mode of action, as they are unlikely to
inhibit protein synthesis by directly binding the bacterial ribosome. Only the detailed evaluation of
the functional properties of myticalins will enable the development of biotechnological applications
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for these novel AMPs. At that stage, specific drug design strategies aimed at improving their stability
and delivery in the target biological systems will need to be carefully taken into account [91,92].
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/8/261/s1,
Figure S1: in vitro coupled transcription/translation in presence of Myticalin A5; Table S1: Presence/absence
patterns of myticalin genes in 20 mussel specimens collected in the gulf of Trieste, Italy; Table S2: list
of transcriptomes screened for the presence of myticalins; Table S3: in silico prediction of myticalin
biological activities.
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